<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20256" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dapsone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kurien</surname>
            <given-names>George</given-names>
          </name>
          <aff>Kerala University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamil</surname>
            <given-names>Radia T.</given-names>
          </name>
          <aff>Allama Iqbal Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>George Kurien declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Radia Jamil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20256.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dapsone is an antibiotic medication&#x000a0;used in&#x000a0;multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis. Initially investigated as an antibiotic agent in 1937, dapsone was first utilized for leprosy treatment in 1945. The drug is also&#x000a0;prescribed for a range of conditions, including both dermatological and non-dermatological ailments.&#x000a0;Dapsone is currently available in both oral and topical formulations.</p>
        <p>Dapsone exerts its antimicrobial action by inhibiting bacterial or folic acid synthesis. In addition, the drug demonstrates anti-inflammatory effects.&#x000a0;The off-label&#x000a0;uses of dapsone include a broad spectrum of dermatoses, as well as prevention and treatment of malaria and <italic toggle="yes">Pneumocystis jiroveci</italic>&#x000a0;(previously known as <italic toggle="yes">Pneumocystis carinii</italic>).&#x000a0;This activity reviews the indications, mechanism of action, administration, adverse event profile, pharmacodynamics, and monitoring of dapsone pertinent to interprofessional healthcare teams involved in the treatment of conditions where dapsone is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between the FDA-approved and off-label uses of dapsone, recognizing its application in various dermatoses, malaria, and <italic toggle="yes">Pneumocystis jiroveci</italic> prevention and treatment.</p></list-item><list-item><p>Implement appropriate dosing regimens for dapsone in both oral and topical formulations, ensuring optimal therapeutic outcomes.</p></list-item><list-item><p>Apply knowledge of dapsone's mechanism of action, combining its antimicrobial and anti-inflammatory effects, to treat diverse dermatologic and non-dermatologic conditions.</p></list-item><list-item><p>Collaborate with other healthcare team members to discuss and address any severe adverse effects or challenges patients encounter during dapsone treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20256&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20256">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20256.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Dapsone is an antibiotic medication&#x000a0;used in&#x000a0;multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis. Although dapsone was initially researched as an antibiotic agent in 1937, it was first used to treat leprosy in 1945.<xref ref-type="bibr" rid="article-20256.r1">[1]</xref>&#x000a0;This drug is available in oral and topical formulations and is also&#x000a0;prescribed for a range of conditions, including both dermatological and non-dermatological ailments. Dapsone exerts its antimicrobial action by inhibiting bacterial or folic acid synthesis.&#x000a0;In addition, the drug demonstrates anti-inflammatory effects.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Paucobilliairy leprosy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multibaciliary leprosy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dermatitis herpetiformis (in adults)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acne vulgaris (as a topical gel)</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses </bold>
<xref ref-type="bibr" rid="article-20256.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Linear IgA bullous dermatosis, chronic bullous dermatosis of childhood, bullous systemic lupus erythematosus, and erythema elevatum diutinum.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune bullous dermatoses such as bullous pemphigoid, cicatricial pemphigoid, IgA pemphigus, subcorneal pustular dermatosis, pemphigus vulgaris, pemphigus foliaceous, and epidermolysis bullosa acquisita.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vasculitic dermatoses&#x000a0;such as leukocytoclastic vasculitis and urticarial vasculitis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neutrophilic dermatoses such as Sweet syndrome, pyoderma gangrenosum, and Behcet syndrome.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other dermatoses such as subacute cutaneous lupus erythematosus, relapsing polychondritis, granuloma annulare, loxoscelism, granuloma faciale, rosacea, panniculitis, pustular psoriasis, nodulocystic acne, and rhinosporidiosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Non-dermatologic off-label indications include&#x000a0;a broad spectrum of dermatoses, as well as prevention and treatment of malaria and&#x000a0;<italic toggle="yes">Pneumocystis jiroveci</italic>&#x000a0;(previously known as&#x000a0;<italic toggle="yes">Pneumocystis carinii</italic>).<xref ref-type="bibr" rid="article-20256.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20256.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>When treating leprosy, dapsone is bacteriostatic against <italic toggle="yes">Mycobacterium leprae</italic> at 1 to 10 mg/L. Dapsone&#x000a0;inhibits the folic acid pathway&#x000a0;by preventing the bacteria from utilizing para-aminobenzoic acid (PABA) to synthesize folic acid&#x000a0;by competitively antagonizing PABA.&#x000a0;Dapsone is also a competitive inhibitor of dihydropteroate synthase.<xref ref-type="bibr" rid="article-20256.r4">[4]</xref></p>
        <p>By&#x000a0;treating conditions with neutrophilic infiltrates in the skin, the drug&#x000a0;exerts therapeutic activity by affecting neutrophilic functions. Dapsone inhibits the myeloperoxidase-peroxide halide-mediated cytotoxic system, a component of the neutrophil respiratory burst. Through&#x000a0;this mechanism,&#x000a0;dapsine controls the degree of&#x000a0;neutrophil-induced destruction in lesions. In leprosy treatment, dapsone exerts&#x000a0;the therapeutic effect by inhibiting the folic acid pathway. It also may inhibit the synthesis of chemotactic lipids and interfere with leukotriene (LTB4) mediated chemotaxis in neutrophils and migration to lesions. Dapsone also decreases the adhesion of neutrophils to IgA.<xref ref-type="bibr" rid="article-20256.r5">[5]</xref></p>
        <p>Though the actual mechanism of action of dapsone is unknown for dermatologic conditions, the drug does affect human neutrophils, perhaps by moderating the level of damage by neutrophils at the site of lesions and by reducing&#x000a0;neutrophil migration to those locations.</p>
        <p>Dapsone&#x000a0;may also exert activity&#x000a0;on eosinophils and monocytes. The efficacy of the drug in conditions like granuloma annulare and eosinophilic cellulitis, in which monocytes and eosinophils have significant roles, respectively, points to this hypothesis.</p>
        <p>The mechanism of topical dapsone in treating acne vulgaris is unknown.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Pharmacokinetic factors for oral dapsone are as follows:</p>
        <p><bold>Absorption:</bold>&#x000a0;Orally ingested dapsone is rapidly and nearly completely absorbed. Dapsone is detectable a few minutes following ingestion and reaches peak concentration in 4 to 8 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;The drug's volume of distribution is estimated&#x000a0;at 1.5 L/kg.<xref ref-type="bibr" rid="article-20256.r6">[6]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;The plasma half-life varies between individuals from 10 to 50 hours, with an average of 28 hours. Repeat tests on the same patient return consistent results. Dapsone is hepatically metabolized by the CYP450 enzyme system, specifically&#x000a0;CYP2E1, and it&#x000a0;is a CYP2C9 and CYP3A substrate.&#x000a0;The drug undergoes metabolism from <italic toggle="yes">N</italic>-acetylation and <italic toggle="yes">N</italic>-hydroxylation.&#x000a0;</p>
        <p><bold>Elimination:</bold>&#x000a0;Approximately 85% of the daily dosage of dapsone is recoverable in the urine as water-soluble metabolites. Dapsone and metabolites are formed in the liver as dapsone glucuronide, which is water-soluble and rapidly excreted via the kidneys.<xref ref-type="bibr" rid="article-20256.r7">[7]</xref>&#x000a0;Drug excretion is slow, and a steady&#x000a0;serum level is maintained with&#x000a0;indicated dosing.</p>
      </sec>
      <sec id="article-20256.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Dapsone is available in 25 mg and 100 mg tablets. Topical dapsone is available in 5% and 7.5% gel formulations.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Leprosy:&#x000a0;</bold>According to the World Health Organization Expert Committee on Leprosy: Eighth Report, there are&#x000a0;3 standard first-line drugs: rifampin (rifampicin), clofazimine, and dapsone. These are fixed-duration multidrug regimens, and none should be&#x000a0;prescribed&#x000a0;as monotherapy. For multibacillary leprosy, the standard adult dose of dapsone is 100 mg by mouth daily for 12 months. The standard child dose is 50 mg orally daily for 12 months. For paucibacillary leprosy, the standard adult dose of dapsone is 100 mg orally daily for&#x000a0;6 months. The standard&#x000a0;oral dosage for children is 50 mg daily for&#x000a0;6 months. Children&#x000a0;younger than&#x000a0;10&#x000a0;should receive appropriately reduced dapsone dosage at 2 mg/kg body weight per day.</p>
        <p><bold>Dermatitis herpetiformis:&#x000a0;</bold>In patients who are&#x000a0;responsive to dapsone, there is a quick reduction in pruritus followed by the clearance of skin lesions. However, there is no effect on the gastrointestinal aspect of the disease. The starting dose for treating dermatitis herpetiformis is 50 mg daily, administered orally, and dapsone should be titrated up to 300 mg daily to achieve the desired effect. A higher dose is given only if the patient is not&#x000a0;responsive to a lower dose. The dose should be reduced to the minimum effective dose of 50 mg to 300 mg per day as soon as possible to avoid potential adverse effects. Dapsone is not indicated in the pediatric patient for this condition.</p>
        <p>The dosing schedule for other dermatoses is the same as&#x000a0;for dermatitis herpetiformis.<xref ref-type="bibr" rid="article-20256.r8">[8]</xref><xref ref-type="bibr" rid="article-20256.r9">[9]</xref></p>
        <p><bold>Acne vulgaris:&#x000a0;</bold>The dapsone dosage for adults and children aged 12 and older is 5% topical gel applied twice daily. Alternatively, the 7.5% gel can be applied topically once daily. For children aged 9 to 11, apply the 7.5% gel once daily.<xref ref-type="bibr" rid="article-20256.r10">[10]</xref></p>
        <p><bold><italic toggle="yes">Pneumocystis (carinii) jiroveci</italic>:&#x000a0;</bold>Dapsone is off-label for the prophylaxis and treatment of P&#x000a0;jiroveci (carinii), which is classified as a fungus. For prophylaxis, the adult dose is 100 mg daily administered by oral route or divided twice a day as monotherapy.&#x000a0;Dapsone&#x000a0;can also be administered orally at 50 mg daily in combination with weekly pyrimethamine and leucovorin. The pediatric dose is also orally administered. For patients older than&#x000a0;1 month, the dose is 2 mg/kg daily, not to exceed 100 mg per day, or 4 mg/kg/dose weekly, not to exceed 200 mg/week. The adolescent dose is 100 mg orally daily or divided twice daily as monotherapy.&#x000a0;Dapsone&#x000a0;can be administered orally at 50 mg daily in combination with weekly pyrimethamine and leucovorin.<xref ref-type="bibr" rid="article-20256.r11">[11]</xref></p>
        <p>To treat P jiroveci, the adult dose is 100 mg daily in combination with trimethoprim for 21 days. The dose is 2 mg/kg daily in conjunction with trimethoprim for 21 days for pediatric patients older than&#x000a0;1 month. For adolescents, the dose is 100 mg daily in combination with trimethoprim for 21 days.</p>
        <p><bold>Toxoplasmosis prophylaxis:&#x000a0;</bold>Dapsone is also used off-label for prophylaxis against toxoplasmosis. The dose is 50 mg oral each day. It is not considered first-line and should be given with pyrimethamine and leucovorin.<xref ref-type="bibr" rid="article-20256.r12">[12]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Hepatic dosing has no specific recommendations, but caution is advised.</p>
        <p><bold>Renal impairment:</bold> No dose adjustments are necessary for patients with renal impairment. If the patient is on hemodialysis, dosing&#x000a0;is after dialysis, with consideration&#x000a0;for a supplemental dose if the subsequent maintenance dose is not due immediately&#x000a0;after dialysis. Peritoneal dialysis requires no dose adjustment and no supplemental dose.</p>
        <p><bold>Pregnancy considerations: </bold>Because&#x000a0;of the lack of data on pregnancy and the drug's potential teratogenicity, dapsone&#x000a0;is given to pregnant females only if&#x000a0;the benefits outweigh the risks. Based on limited data from human studies, there is a risk of teratogenicity and hemolytic anemia.<xref ref-type="bibr" rid="article-20256.r13">[13]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>There is a potential risk of infant hemolytic anemia based on the drug's mechanism of action and limited data from human studies; therefore, clinicians must assess the risks and benefits for breastfeeding women.<xref ref-type="bibr" rid="article-20256.r13">[13]</xref></p>
        <p><bold>Pediatric patients: </bold>Pediatric patients receive treatment using the same schedule as adults but with smaller dosages. No data point&#x000a0;to dapsone affecting children's later growth and functional development. Dapsone topical is not recommended for children younger than 9.</p>
        <p><bold>Older patients:&#x000a0;</bold>No data implicate that dapsone needs special dose adjustments in oral or topical dose forms in older patients.</p>
      </sec>
      <sec id="article-20256.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of oral dapsone include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hematologic: Hemolytic anemia, aplastic anemia, methemoglobinemia, leukopenia, and agranulocytosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cutaneous hypersensitivity reactions: Mebilliform eruption,&#x000a0;exfoliative erythroderma, drug-induced lupus erythematosus, and toxic epidermal&#x000a0;necrolysis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neurologic: Peripheral neuropathy, predominantly motor loss</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psychiatric: Psychosis and insomnia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eyes: Blurred vision</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ear, nose, and throat: Tinnitus and vertigo</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac: Tachycardia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary: Pulmonary eosinophilia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic: Hepatitis, dapsone syndrome, cholestatic jaundice, and hypoalbuminemia without proteinuria</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal: Nausea, vomiting, abdominal pain, anorexia, and pancreatitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal:&#x000a0;Nephrotic syndrome, albuminuria, and renal papillary necrosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dapsone syndrome: Usually develops after 2 to 6 weeks of dapsone therapy. The characteristic presentation is fever, rash, and hepatitis. The clinical picture may resemble infectious mononucleosis. Blood work will show peripheral eosinophilia and elevated liver enzymes. It&#x000a0;is life-threatening if inadequately treated.<xref ref-type="bibr" rid="article-20256.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>The adverse reactions that may occur with topical dapsone include methemoglobinemia, angioedema, dryness, peeling, erythema, and oily skin.</p>
      </sec>
      <sec id="article-20256.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The contraindications for dapsone in different formulations are listed below.</p>
        <p>
<bold>Oral Dapsone</bold>
</p>
        <p>Absolute contraindications to the use of dapsone are prior hypersensitivity to dapsone or its derivatives, including agranulocytosis and hypersensitivity syndrome. Deaths from agranulocytosis, aplastic anemia, and other blood dyscrasias&#x000a0;are reported with dapsone administration.<xref ref-type="bibr" rid="article-20256.r15">[15]</xref></p>
        <p>Relative contraindications to using dapsone include allergy to sulfonamide antimicrobials, significant cardiopulmonary disease, significant liver or renal function impairment, glucose-6-phosphate 1-dehydrogenase (G6PD) deficiency, methemoglobinemia, or pre-existing peripheral neuropathy.&#x000a0;For the treatment of pregnant women, dapsone is a category C drug. Therefore, it should be used cautiously and only if the benefits outweigh the risks.<xref ref-type="bibr" rid="article-20256.r16">[16]</xref></p>
        <p>
<bold>Topical Dapsone</bold>
</p>
        <p>G6PD deficiency&#x000a0;and methemoglobinemia also represent contraindications to topical dapsone.</p>
      </sec>
      <sec id="article-20256.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The following monitoring parameters apply to orally administered dapsone.&#x000a0;Topical dapsone requires no routine monitoring.</p>
        <p>
<bold>Baseline</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete history and physical with emphasis on cardiopulmonary, gastrointestinal, neurologic, and renal systems</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lab: Complete blood count, differential count, liver function tests, renal function tests, G6PD level, and urinalysis&#x000a0;<xref ref-type="bibr" rid="article-20256.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Follow-Up</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count (CBC) with differential every week for&#x000a0;4 weeks, then every&#x000a0;2 weeks until week 12, then every 3 to 4 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reticulocyte count as needed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Liver function tests and renal function tests every 3 to 4 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methemoglobin level as clinically indicated.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20256.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Dapsone-induced methemoglobinemia typically results from acute&#x000a0;poisoning,&#x000a0;either by accidental ingestion or suicidal intent. Presenting symptoms include headache, fatigue, tachycardia, dizziness, and weakness. More severe cases (levels above 60%) can result in arrhythmias, dyspnea, seizures, or coma. Methemoglobinemia is treatable with gastric decontamination, early administration of activated charcoal, or intravenous (IV) methylene blue.<xref ref-type="bibr" rid="article-20256.r18">[18]</xref><xref ref-type="bibr" rid="article-20256.r19">[19]</xref></p>
      </sec>
      <sec id="article-20256.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional healthcare team, comprising physicians, advanced practice practitioners, nursing staff, and pharmacists, must collaborate to guarantee patient compliance with dapsone prescriptions. Team members need to communicate and address any severe drug adverse effects the patient may encounter, such as rash and jaundice, during their treatment. Some cases may require an infectious disease specialist and/or an infectious disease specialty pharmacist. These specialists&#x000a0;are updated with the latest antibiogram data and can recommend dosing adjustments or alternative therapies.</p>
        <p>All patient encounters and interventions must be documented in the medical record so that every team member can access the same current and updated information. Open communication can preclude adverse events and make all team members aware of concerns that may arise during monitoring. This interprofessional approach drives optimal patient outcomes.</p>
      </sec>
      <sec id="article-20256.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20256&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20256">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20256/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20256">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20256.s11">
        <title>References</title>
        <ref id="article-20256.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>YI</given-names>
              </name>
              <name>
                <surname>Stiller</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Dapsone and sulfones in dermatology: overview and update.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-34</page-range>
            <pub-id pub-id-type="pmid">11511841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soter</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>155</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-95</page-range>
            <pub-id pub-id-type="pmid">30476976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Rabay</surname>
                <given-names>FMO</given-names>
              </name>
              <name>
                <surname>Lira</surname>
                <given-names>MLA</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatosis of the dorsal hands: response to dapsone monotherapy.</article-title>
            <source>An Bras Dermatol</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>730</fpage>
            <page-range>730-732</page-range>
            <pub-id pub-id-type="pmid">30156627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Re: Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-2015.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2019</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>644</fpage>
            <page-range>644-645</page-range>
            <pub-id pub-id-type="pmid">30583054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Din</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Tsiaras</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Mostaghimi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Systemic Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Review.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1058</fpage>
            <page-range>1058-1060</page-range>
            <pub-id pub-id-type="pmid">30365585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bandyopadhyay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wootton</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Duparc</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Winstanley</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>977</fpage>
            <page-range>977-87</page-range>
            <pub-id pub-id-type="pmid">19517101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rato</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Rigor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mota</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hansen's disease - a forgotten disease?</article-title>
            <source>JRSM Open</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>20542704211035995</fpage>
            <pub-id pub-id-type="pmid">34484802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Two Cases of Dermatitis Herpetiformis Successfully Treated with Tetracycline and Niacinamide.</article-title>
            <source>Acta Dermatovenerol Croat</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-275</page-range>
            <pub-id pub-id-type="pmid">30390734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghaoui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kibbi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kurban</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on the use of dapsone in dermatology.</article-title>
            <source>Int J Dermatol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>787</fpage>
            <page-range>787-795</page-range>
            <pub-id pub-id-type="pmid">31909480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Searle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Al-Niaimi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Dapsone for acne: Still in use after half a century!</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>2036</fpage>
            <page-range>2036-2039</page-range>
            <pub-id pub-id-type="pmid">33600049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyant</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kabbani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doucette</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pneumocystis jirovecii: a review with a focus on prevention and treatment.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>1579</fpage>
            <page-range>1579-1592</page-range>
            <pub-id pub-id-type="pmid">33870843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wozel</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Innovative use of dapsone.</article-title>
            <source>Dermatol Clin</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>599</fpage>
            <page-range>599-610</page-range>
            <pub-id pub-id-type="pmid">20510768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozturk</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tatliparmak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Leprosy treatment during pregnancy and breastfeeding: A case report and brief review of literature.</article-title>
            <source>Dermatol Ther</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">27549245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thangaraju</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Venkatesan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Leprosy cases with respiratory infection - Rule out tuberculosis simultaneously with dapsone syndrome.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>215</fpage>
            <page-range>215-216</page-range>
            <pub-id pub-id-type="pmid">30505060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>ZG</given-names>
              </name>
            </person-group>
            <article-title>Subtle case of dapsone-induced methaemoglobinaemia.</article-title>
            <source>BMJ Case Rep</source>
            <year>2020</year>
            <month>Aug</month>
            <day>24</day>
            <volume>13</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">32843412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radeva-Petrova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kayentao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>ter Kuile</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Oct</month>
            <day>10</day>
            <volume>2014</volume>
            <issue>10</issue>
            <fpage>CD000169</fpage>
            <pub-id pub-id-type="pmid">25300703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lor</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Kransdorf</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kobashigawa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Dapsone-Associated Anemia in Heart Transplant Recipients with Normal Glucose-6-Phosphate Dehydrogenase Activity.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Oct</month>
            <day>28</day>
            <volume>11</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">36362606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tandon</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A rare case of toxic brain injury with methaemoglobinaemia: Dapsone, the culprit.</article-title>
            <source>Natl Med J India</source>
            <year>2022</year>
            <season>Sep-Oct</season>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>317</fpage>
            <pub-id pub-id-type="pmid">37167496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20256.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alyahya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alalshaikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sabbahi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alnowiser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Mohawes</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Methylene Blue Infusion to Treat Severe Dapsone-Induced Methemoglobinemia in a Pediatric Patient.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e18853</fpage>
            <pub-id pub-id-type="pmid">34804706</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
